Related Experiment Video
Updated: Mar 16, 2026

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
Published on: March 21, 2021
Clinical Implications of Sarcopenic Obesity in Cancer
Isabella P Carneiro1, Vera C Mazurak1, Carla M Prado2
1Department of Agricultural, Food, and Nutritional Science, Faculty of Agricultural, Life, and Environmental Sciences, University of Alberta, 4-002 Li Ka Shing Centre for Health Innovation, Edmonton, AB, T6G 2E1, Canada.
Abstract:
Sarcopenia has been associated with several negative clinical outcomes in cancer. However, the consequences of sarcopenic obesity, a condition of combined sarcopenia and obesity burden, have been less extensively investigated. The aim of this paper was to review the current evidence on the prevalence and clinical implications of sarcopenic obesity in cancer. A total of 14 studies linking sarcopenic obesity to a clinical outcome in cancer were included. There is considerable inconsistency in methods used to evaluate body composition as well as in the criteria used to define sarcopenic obesity, which limits comparison among studies. Therefore, the prevalence of sarcopenic obesity varied substantially: between 1 and 29 % in studies including individuals from all body mass index categories and between 15 and 36 % for those including obese individuals only. Negative clinical outcomes reported to be associated with sarcopenic obesity included higher risk of dose-limiting toxicity, surgical complications, physical disability, and shorter survival.
Related Concept Videos
Cancer Survival Analysis
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Psychoneuroimmunology: Diabetes and Cancer
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Prevention
Some...
Drug Dosing: Obese Patients

